The poor outcomes of preterm birth and stillbirth were observed primarily with those infected with SARS-CoV-2 during the first or second trimester, whereas increased rates of small for gestational age were driven largely by third trimester infection.
An Institute for Systems Biology-led study examined the electronic health records of more than 18,000 people with SARS-CoV-2 tests during pregnancy.
Researchers compared outcomes of unvaccinated people with a positive test during pregnancy 882 in total to those who tested negative.
The people in the study had mild or moderate SARS-CoV-2 infections. Severity of maternal COVID-19 infection was not correlated with gestational age at delivery.
Additionally, poor birth outcomes were present even if maternal COVID-19 didn't result in severe respiratory problems during infection.
The findings were published in the journal The Lancet Digital Health and are among the first that account for the trimester of SARS-CoV-2 infection on birth outcomes.
People in the SARS-CoV-2-positive cohort were more likely to have Hispanic ethnicity, race other than Asian or White, Medicaid insurance, lower age, higher BMI, lower education attainment, and other factors known to be associated with negative birth outcomes.
To account for this and to make a true apples-to-apples comparison, researchers used a statistical matching technique that controlled for the confounding variables.
The study was conducted before COVID-19 vaccines were widely available in the United States. There is an opportunity for future studies to examine whether vaccination helps to prevent negative birth outcomes in breakthrough cases.
This research project was a collaboration between ISB and Providence.
Institute for Systems Biology is a Seattle-based non-profit biomedical research organization. We focus on some of the most pressing issues in human health, including aging, autoimmune diseases, brain health, cancer, and many infectious diseases.
ISB is an affiliate of Providence, one of the nation's largest not-for-profit health care systems.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial